Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 3/20 | 0.38 |
| ▸ | PTPRG | P23470 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941188 | 0.87 | L3MBTL1 (0.51) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL1943028 | 0.86 | PTPRC (0.48) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL1941172 | 0.84 | PKM (0.52) | HPGDCCR2ALDH1A1LMNASCN9A | |
| SCHEMBL4018614 | 0.83 | L3MBTL1 (0.52) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL1940433 | 0.81 | L3MBTL1 (0.52) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL4024240 | 0.80 | L3MBTL1 (0.54) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL1941473 | 0.80 | KDR (0.48) | L3MBTL1CYP2C9CCR2ALDH1A1LMNA | |
| SCHEMBL1941095 | 0.78 | L3MBTL1 (0.53) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL1940258 | 0.75 | L3MBTL1 (0.50) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 | |
| SCHEMBL1942772 | 0.75 | L3MBTL1 (0.57) | L3MBTL1CYP1A2CYP3A4ALPGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717229-B1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1717229-A1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | L3MBTL1 2780/4885CYP1A2 3017/4885CYP3A4 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.